Latest Obroncology Podcast Episodes
“Major Wins” in Lung Cancer Treatment: How “Explosion of Data” Is Changing Practice
Peer-Spectives - May 09, 2023 15:20 - 11 minutesWithin the last few years, an “explosion of data” regarding adjuvant and neoadjuvant treatment for resectable lung cancer has contained “major wins” for patient care. Although exciting, the rapid advancement has led to questions about when chemotherapy and chemoimmunotherapy should be adopted o...
“Great Therapies for All-Comers” in CLL: How Can Oncologists “Pick and Choose?”
Peer-Spectives - April 18, 2023 15:02 - 14 minutesAs treatment options increase for patients with CLL, so do questions about which interventions, if any, are right for which patients and when. Bob Figlin, MD, and Nicole Lamanna, MD, discuss key considerations, ranging from cardiac toxicity to why Dr. Lamanna “won't just treat for a symptom.”
Pragmatica-Lung Tests a Treatment and a New Approach to Trials
Peer-Spectives - March 17, 2023 17:09 - 9 minutesThe newly opened Pragmatica-Lung trial compares ramucirumab plus pembrolizumab versus usual care for treatment of stage IV or recurrent non-small cell lung cancer. The trial is designed to ease enrollment requirements and data collection needs, focusing on the key endpoint of overall survival. L...
The Best First Step in Metastatic NSCLC Care
Peer-Spectives - March 10, 2023 20:24 - 9 minutesWith more than 10 known driver mutations in non-small cell lung cancer (NSCLC), testing is ever more critical, says Heather Wakelee, MD, division chief of medical oncology at Stanford University and president of the International Association for the Study of Lung Cancer. Listen as she and Peer-...
Neo- and Adjuvant Treatments Are Changing Care in Early NSCLC
Peer-Spectives - March 06, 2023 16:30 - 11 minutesTreatment options are expanding quickly in early non-small cell lung cancer. Listen as Heather Wakelee, MD, division chief of Medical Oncology at Stanford University and president of the International Association for the Study of Lung Cancer, describes how she’s using new agents and incorporati...
NALIRIFOX Changes Care in Pancreatic Cancer: Here’s How
Peer-Spectives - February 16, 2023 00:13 - 10 minutesAfter a decade of limited gains in metastatic pancreatic cancer, Zev Wainberg, MD, professor of medicine and co-director of the GI oncology program at the University of California, Los Angeles, presented the results of the NAPOLI-3 trial at the ASCO Gastrointestinal Cancers Symposium last month....
Matching Breast Cancer Patients to Therapies: Here’s How
Peer-Spectives - December 16, 2022 01:35 - 11 minutes - VideoThe landscape for breast cancer treatment is shifting quickly, with an ever-increasingemphasis on targeted and hormonal therapies. Listen as Virginia Kaklamani,MD, professor of medicine in the division of hematology oncology at UT Health San Antonio, and medical directorof the breast oncologypr...
Myelofibrosis Remains Tough to Treat, But New Drugs Are Paving the Way
Peer-Spectives - November 11, 2022 22:14 - 13 minutesListen as Gabriela Hobbs, MD, clinical director of the leukemia atMass General, talks with Bob Figlin, MD, the Steven Spielberg Family Chair in Hematology Oncology at Cedars-Sinai Cancer in Los Angeles, about the latest progress in the treatment of myelofibrosisand how she both assesses new pati...
KRAS Inhibition in NSCLC: When, How, and Why?
Peer-Spectives - November 11, 2022 16:55 - 14 minutesMelissa Johnson, MD,a medical oncologist with Tennessee Oncology and Director of Lung Cancer Research at Sarah Cannon Research Institute in Nashville,joins host Robert Figlin, MD, Steven Spielberg Family Chair in HematologyOncologyat Cedars-Sinai Cancer, to talk about KRAS G12C inhibition in non...
Strategies for Navigating a Hematology/Oncology Fellowship
Peer-Spectives - November 04, 2022 20:55 - 14 minutesThe key steps to launching a successful and professionally fulfilling hematology/oncology fellowship is to “reflect, project, and adapt,” according to Gerald Hsu, MD, PhD, associate clinical professor of medicine and director of the Hematology/Oncology Fellowship Program at UCSF. Dr. Hsu spoke w...
Taking Aim at MET and KRAS in NSCLC
Peer-Spectives - October 29, 2022 21:29 - 12 minutesTejas Patil, MD, assistant professor of medical oncology at the University of Colorado Cancer Center, talks with Robert A. Figlin, MD, about new targeted therapies for non-small cell lung cancer (NSCLC), particularly tepotinib (Tepmetko) for MET exon 14 and sotorasib (Lumakras) for KRAS G12C. Th...
Mantle Cell Lymphoma: Optimizing Current Therapies
Peer-Spectives - October 28, 2022 15:14 - 12 minutesJonathan Cohen, MD, MS, Associate Professor, Hematology and Medical Oncology, Emory University School of Medicine, , joins OBR Editor-in-Chief Robert Figlin, MD, to talk about mantle cell lymphoma. Dr. Cohen describes the key to making a correct diagnosis and what the best frontline treatmen...
COSMIC-313 trial and the Complex Treatment Landscape for Metastatic Renal Cell Cancer: How Do You Decide?
Peer-Spectives - October 19, 2022 21:06 - 12 minutesBob Figlin, MD, and Toni Choueiri, MD, the director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, discuss the early results from the COSMIC-313 trial, which Dr. Choueiri presented at ESMO 2022. The trial enrolled previously untreated patients with metastatic clea...
Finding Joy in Work: ASCO’s Career Development Resources Help Trainees Choose Their Path
Peer-Spectives - October 04, 2022 21:25 - 14 minutesBob Figlin, MD, and Jamie Von Roenn, MD, discuss strategies for learning about the oncology specialty earlier in the training pipeline, particularly for under-represented groups. They also look at opportunities for oncology fellows to build skills in different career areas.
Considering an Oncology Fellowship? Listen to This First
Peer-Spectives - September 06, 2022 19:36 - 17 minutesGerald Hsu, MD, PhD, UCSF’s hematology/oncology fellowship program director, joins Robert Figlin, MD, to talk about what fellowship programs are looking for in applicants, how trainees can find programs that are a good fit, and why preparing for an interview improves the odds you land at the rig...
Kidney Cancer at a Crossroads: What New Trial Results Could Mean for Patients
Peer-Spectives - August 19, 2022 14:08 - 13 minutesMichael B. Atkins, MD, and Robert Figlin, MD, discuss results from the EVEREST clinical trial as well as new data on TKIs, immunotherapy, and HIF-2 inhibitors. They also discuss adjuvant therapy and how depth of response differs between immunotherapy and TKIs, and look ahead to what the future ...
How to Choose CLL Treatments in the Frontline Setting
Peer-Spectives - July 08, 2022 17:28 - 11 minutesDanielle Brander, MD, talks with Robert Figlin, MD, about selecting frontline treatments for CLL and how she talks with patients about their treatment options. “What I think is unique about the last few years is we’ve seen multiple randomized trials in the frontline setting that have shown not ...
Rethinking HER2-Targeted Therapy After DESTINY-04
Peer-Spectives - July 07, 2022 19:34 - 11 minutesWilliam Gradishar, MD, talks with Robert Figlin, MD, about breast cancer research highlights from the 2022 American Society of Clinical Oncology Annual Meeting, including results from DESTINY-Breast04 and new data on CDK4/6 inhibitors from the PALOMA-2 and MAINTAIN trials.
Most Patients with BRAF-mutant Metastatic Melanoma Benefit from First-line Immunotherapy
Peer-Spectives - June 16, 2022 21:47 - 12 minutesMichael B. Atkins, MD, talks with Robert A. Figlin, MD, about the importance of sequencing therapies for patients with BRAF-positive metastatic melanoma. Data from the DREAMSeq trial, which Dr Atkins updated at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, show a signifi...
Adjuvant and Neoadjuvant Therapy for NSCLC: Who to Treat and With What Agent
Peer-Spectives - May 05, 2022 01:46 - 12 minutesListen in as Roy Herbst, MD, PhD, shares with Robert Figlin, MD, how he approaches treatment for patients with early-stage non-small cell lung cancer after the ADAURA and CHECKMATE-816 trials. They discuss different factors that influence use of adjuvant and neoadjuvant treatments, including sta...
The Complex Decisions in CLL Treatment Today: Clarifying the Choices
Peer-Spectives - April 13, 2022 14:57 - 13 minutesLori Leslie, MD, and Robert Figlin, MD, discuss the latest drugs and clinical trial data on CLL treatment. Dr. Leslie shares her strategy for sequencing agents, including various BTK inhibitors and venetoclax, and how she decides on treatment in patients whose disease progresses or are refractory.
DREAMseq Trial: What It Means for Metastatic Melanoma Treatment
Peer-Spectives - March 29, 2022 19:14 - 11 minutesSapna Patel, MD, Associate Professor at MD Anderson Cancer Center, and Robert Figlin, MD, Deputy Director at Cedars-Sinai Cancer, discuss the clinical implications of the DREAMseq trial, showing patients with BRAF-mutant metastatic melanoma live longer if they receive first-line ipilimumab plus ...
The Latest Thinking Regarding Adjuvant Pembrolizumab in Renal Cell Carcinoma Post-ASCO GU ‘22
Peer-Spectives - March 11, 2022 16:39 - 21 minutesRana McKay, MD, Allan Pantuck, MD, and Robert Figlin, MD, discuss the recent update to the Keynote-564 study investigating adjuvant pembrolizumab in RCC and the impact on high-, medium-, and low-risk patients. They also talk about the Disease-Free Survival (DFS) endpoint, discussing the study w...
Post ASCO GU ’22 – Muscle-Invasive Bladder Cancer, EV-103, Enfortumab Vedotin, and the Clinical Progress Being Made Managing MIBC Patients
Peer-Spectives - March 07, 2022 16:30 - 9 minutesDaniel Petrylak, MD, Professor of Medicine at the Yale Cancer Center, and Robert Figlin, MD, of Cedars-Sinai Cancer discuss recent developments at ASCO GU in muscle-invasive bladder cancer and in particular the EV-103 clinical study while also discussing the future of MIBC treatment.
The HIMALAYA Study Presented at ASCO GI ’22: An Update on the State of Liver Cancer Treatment Today
Peer-Spectives - January 26, 2022 22:54 - 10 minutesGhassan Abou-Alfa, MD and Robert Figlin, MD, discuss the presentation of the HIMLAYA clinical study at ASCO GI ’22 and how this regimen may fit in the liver cancer treatment landscape
Frederick Locke, MD of Moffit Cancer Center and Robert Figlin, MD of Cedars-Sinai discuss ZUMA-7, the role of CAR-T in the management of relapsed/refractory B-cell lymphoma, and recent clinical data presented at ASH ‘21
Peer-Spectives - December 22, 2021 21:35 - 11 minutesFrederick Locke, MD and Robert Figlin, MD discuss ZUMA-7 and when to start thinking about integrating CAR-T into B-cell lymphoma treatment algorithms, the role of BMT in these patients, and how recent data presented at ASH ’21 shows that CAR-T cell therapies can work well in relapsed/refractory ...
From SABCS ’21: Neoadjuvant Immunotherapy and the Use of the 21-Gene Signature Test
Peer-Spectives - December 14, 2021 18:12 - 11 minutesLajos Pusztai, MD, and Robert Figlin, MD, discuss the practicality of neoadjuvant I-O as demonstrated in KEYNOTE-522 and the application of the Oncotype DX 21-gene signature test in the RxPONDER study, both presented at the 2021 San Antonio Breast Cancer Symposium.
Targeted Therapy and Venclexta Combinations for AML and a Look Ahead to ASH ’21
Peer-Spectives - December 02, 2021 15:44 - 11 minutesNaval Daver, MD, and Robert Figlin, MD, discuss FLT3, TP53, and venetoclax combinations in the management of AML patients and what to look forward to at ASH 2021.
After CodeBreaK100:
Peer-Spectives - November 20, 2021 02:36 - 11 minutesKathryn Arbour, MD, joins host Robert Figlin, MD, to discuss the importance of the KRAS-targeted drug, sotorasib, in the treatment of non-small cell lung cancer. Kathryn Arbour, MD, joins host Robert Figlin, MD, to discuss the role next-generation sequencing plays in lung cancer care, the resp...
ESMO ’21: The ARCHES Study and Progress in Metastatic (and Non-Metastatic) Hormone-Sensitive Prostate Cancer
Peer-Spectives - September 22, 2021 21:28 - 9 minutesAndrew Armstrong, MD and Robert Figlin, MD discuss the ARCHES study investigating the role of enzalutamide in metastatic hormone-sensitive prostate cancer, followed by a discussion of the latest treatment trends in non-metastatic hormone-sensitive prostate cancer.
Related Obroncology Topics